The role of biphosphonates in the treatment of pain in patients with the dissemination to skeletal system;Rola bifosfonianów w leczeniu bólu u chorych z rozsiewem do układu kostnego

Onkologia Polska

Volumn 10, Issue 4, 2007, Pages 164-168

  Leppert, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Biphsphonates; Bone metastases; Bone pain; Hypercalcemia; Skeletal related events

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; QUALITY OF LIFE; SPINAL CORD COMPRESSION; VERTEBRA FRACTURE; WORLD HEALTH ORGANIZATION;

EID: 40249088483     PISSN: 15056732     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Charliński G., JQdrzejczak W.W.: Nowe dwufosfoniany w leczeniu nowotworowych zmian w kościach. Wspólcz. Onkol. 2004, 8, 86-95.
2. Zuchowska-Vogelgesang B.: Rola bifostonianów w leczeniu przerzutów nowotworowych do koćsci. [w:] Leczenie przerzutów nowotworowych do kości, Pawlicki M. (red.). Alfa-Medica Press, Bielsko-Biala 1997,86-98.
3. Najda J.: Profil bezpieczeństwa stosowania bifosfonianów we wskazaniach onkohematologicznych. Acta Haemat. Pol. 2005, 36, supl. 2,1-8.
4. Coleman R. E.: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001, 27, 165-176.
5. Coukell A.J., Markham A.: Pamidronate: A Review of its Use in the Management of Osteolytic Bone Metastases, Tumour-induced Hypercal-caemia and Paget's Disease of Bone. Drugs Aging 1998,12,149-168.
6. Hillner B. E., Ingle J.N., Chlebowski R.T. i wsp.: American Society of Clinical Oncology 2003 Update on the Role of Biphosphonates and Bone Health Issues in Women with Breast Cancer. J. Clin. Oncol. 2003, 21, 4042-4057.
7. Michaelson M.D., Smith M.R.: Biphosphonates for treatment and prevention of bone metastases. J. Clin. Oncol. 2005, 23, 8219-8224.
8. Oh W.K., Proctor K., Nakabayashi M. i wsp.: The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007, 109, 1090-1096.
9. Champallou C., Basayau J.P., Veyret C. i wsp.: Hypocalcemia Following Pamidronate Administration for Bone Metastases of Solid Tumor: Three Clinical Case Reparts. J. Pain Symptom Manage. 2003, 25,185-190.
10. Ruggiero S.I., Mehrotra B., Rosenberg T.J., Engroff S.L.: Osteonecrosis of the jaws associated with the use of biphosphonates: a review of the 63 cases. J. Oral Maxillofac. Surg. 2004, 62, 527-534.
11. Bamias A., Kastritis E., Bamia C. i wsp.: Osteonecrosis of the Jaw in Cancer After Treatment With Biphosphonates: Incidence and Risk Factors. J. Clin. Oncol. 2005, 23, 8580-8587.
12. Kraj M., Poglód R., Maj S. i wsp.: Martwica żuchwy zwiazana ze stosowaniem kwasu zoledronowego u chorych na szpiczaka plazmocytowego. Nowotwory 2006, 56,185-189.
13. Conte P. F., Guarneri V.: Safety of intravenous and oral biphosphonates and compliance with dosing regimens. Oncologist 2004, 9, supl. 4, 28-37.
14. Diel U.: Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support. Care Cancer 2007, 15, 1243-1249.
15. Wong R., Wiffen P.J.: Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CDO02068. DOI: 10.1002/14651858.CD002068
16. Ross J.R., Saunders Y., Edmonds P.M. i wsp.: Systematic review of the role of biphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003, 327, 469-475.
17. Body J.J., Mancini I.: Biphosphonates for cancer patients: why, how, and when? Support. Care Cancer 2002,10, 399-407.
18. Clemins M., Enright K., Cesta A. i wsp.: Do physicians follow systemic treatment and funding policy guidelines? A review of biphosphonate use in patients with bone metastases from breast cancer. Can. J. Clin. Pharmacol. 2004,11, 168-178.
19. Goodwin P.J., Black J.T., Bordeleau L.J., Ganz P.A.: Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer- Taking Stock. J. Natl. Cancer Inst. 2003, 95, 263-281.
20. Joly F., Vardy J., Pintillie M., Tannock I.F.: Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann. Oncol. 2007, doi: 10.1093/annonc/mdml2l, opublikowano on-line 13 sierpnia 2007.
21. Krzakowski M., Pieńkowski T.: Zabuizenia metaboliczne i wodno-elektrolitowe u chorych na nowotwory. [w:] Onkologia kliniczna, Krzakowski M. Tom I, Wydawnictwo Medyczne Borgis, Warszawa 2006, 477-488.
22. Pawlak W.Z., Wawrocka-Pawlak M.: Hiperkalcemia w chorobie nowotworowej- patolizjologia, diagnostyka, leczenie. Wspólcz. Onkol. 2004, 7,482-496.
23. Nussbaum S.R., Younger J., Vandepol G.J. i wsp.: Single-dose intravenous therapy with pamidronate for the treatment of hypercalcaemia of malignacy: comparison of 30-, 60-, and 90 mg dosages. Am. J. Med. 1993, 95, 297-304.
24. Drosik K., Krzakowski M., Jarosz J. i wsp.: Bisfosfoniany wzapobieganiu i kontroli zdarzeń kostnych u chorych z przerzutami nowotworów zlośliwych do kości. Onkol. Prakt. Klin. 2006, 2, 152-164.
25. Spizanazze S., Schrijvers D.: Metabolic Emergencies. Crit. Rev. Oncol. Hematol. 2006, 58, 79-89.